Significant Accounting Policies - Additional Information (Details) - USD ($)					3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 14, 2022	Oct. 12, 2021	Mar. 19, 2021	Jan. 25, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2022	Oct. 04, 2021
Schedule Of Significant Accounting Policies [Line Items]
Reimbursement payment			$ 14,000,000.0
Expected term of stock option granted to employees and directors, average contractual term and vesting period							10 years
Collaboration agreement amount			25,000,000.0
Development payments			10,000,000.0
Deferred collaboration funding, current					$ 181,888		$ 181,888			$ 8,412,971
Deferred collaboration funding, non-current					4,365,310		4,365,310
Cash in excess of FDIC insured limit					1,300,000		1,300,000			2,100,000
Income tax expense (benefit)					0	$ 0	0	$ 0
Uncertain tax positions, accruals					0		0			0
Accruals for interest or penalties related to income tax matters					$ 0		$ 0			0
ASU No. 2016-13
Schedule Of Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]					true		true
Change in Accounting Principle, Accounting Standards Update, Adoption Date					Mar. 31, 2023		Mar. 31, 2023
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]					true		true
Accounts Payable and Accrued Expenses
Schedule Of Significant Accounting Policies [Line Items]
Preclinical or clinical study expense					$ 1,100,000		$ 1,100,000			$ 900,000
Maximum
Schedule Of Significant Accounting Policies [Line Items]
Cash, FDIC insured amount					250,000		250,000
Collaboration Agreement | Second Development Payment
Schedule Of Significant Accounting Policies [Line Items]
Deferred collaboration funding					4,500,000		4,500,000
Deferred collaboration funding, current					200,000		200,000
Deferred collaboration funding, non-current					4,300,000		4,300,000
Deferred collaboration funding, cash received					$ 35,000,000.0		$ 35,000,000.0
Revenue recognized									$ 1,300,000
Offset to research and development expenses									15,200,000
Offset to general and administrative expenses									14,000,000.0
Collaboration Agreement | Relief
Schedule Of Significant Accounting Policies [Line Items]
Cash payment received			10,000,000.0						$ 10,000,000.0
Reimbursement payment			14,000,000.0	$ 14,000,000.0
Repayment of promissory note of prior loan and interest			$ 4,000,000.0
Net profit split ratio based on territory			60.00%	60.00%
Percentage of royalty net sales received			15.00%	15.00%
Milestone payment to be received			$ 6,000,000.0	$ 6,000,000.0
Proceeds from development payments subject to acceptance of new drug application											$ 10,000,000.0
Development and commercialization services and reliefs right of profit percentage			60.00%
Percentage of payment net profit territory			60.00%
Upfront non-refundable payment received				$ 1,000,000.0
Development payments			$ 20,000,000.0
Collaboration Agreement | Relief | Secured Loan
Schedule Of Significant Accounting Policies [Line Items]
Debt instrument, term				12 months
Debt instrument, principal amount				$ 4,000,000.0
Debt instrument, interest rate				6.00%
Collaboration Agreement | Relief | Maximum
Schedule Of Significant Accounting Policies [Line Items]
Development payments			20,000,000.0	$ 20,000,000.0
Waiver and Agreement | Relief | Second Development Payment
Schedule Of Significant Accounting Policies [Line Items]
Proceeds from first tranche of development payments subject to new drug application		$ 5,000,000.0
Proceeds from second tranche of development payments subject to new drug application	$ 5,000,000.0
Collaboration and License Agreement
Schedule Of Significant Accounting Policies [Line Items]
Upfront non-refundable payment received			$ 1,000,000.0